Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Request metadata listed "SELLAS Life Sciences," but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Reporting Period: Quarterly period ended September 30, 2008 (Form 10-Q).
Business Overview: RXi is a development-stage biopharmaceutical company focused on discovering proprietary therapeutics based on RNA interference (RNAi) for neurodegenerative, metabolic, and inflammatory diseases. The company has generated no revenue since inception and relies on equity financing and potential partnerships to fund operations.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(3,408,000) | $(10,372,000) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.25) | $(0.79) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,664,000 |
| Short-Term Investments | N/A | N/A | $9,015,000 |
| Total Current Assets | N/A | N/A | $13,005,000 |
| Total Current Liabilities | N/A | N/A | $1,180,000 |
| Accumulated Deficit | N/A | N/A | $(21,362,000) |
Cash Flow (Nine Months Ended Sep 30, 2008):
- Net cash used in operating activities: $(6,694,000)
- Net cash provided by investing activities: $694,000
- Net cash provided by financing activities: $7,901,000
Material Changes vs. Prior Period
- Operating Loss: The net loss for the three months ended September 30, 2008, increased by 55% to $3.4 million compared to $2.2 million in the same period in 2007. For the nine-month period, the net loss increased by 24% to $10.4 million from $8.4 million.
- Expenses:
- Research & Development (R&D): Increased 53% quarter-over-quarter to $1.2 million, driven by higher staff costs and stock-based compensation ($167,000 vs. $80,000). For the nine months, R&D expenses decreased slightly by 6% to $5.1 million due to lower costs associated with issuing stock for licensing rights, partially offset by higher compensation costs.
- General & Administrative (G&A): Increased 43% quarter-over-quarter to $2.3 million and 66% for the nine months to $5.5 million. Increases were driven by stock option/warrant compensation ($1.14 million in Q3) and costs associated with being a public company (legal, SEC filings, investor relations).
- Interest Income: Decreased significantly due to declining interest rates. Q3 interest income dropped to $56,000 from $171,000 in the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and short-term investments ($12.7 million total) are sufficient to fund operations through the second half of 2009.
- Future Funding: The company expects to incur significant operating losses for the foreseeable future. It will be dependent on obtaining additional funding from third parties (equity, debt, or collaborations) to maintain operations and meet obligations. There are no current commitments for future funding.
- Risks: Failure to obtain additional funding could force the company to scale back or terminate operations, or seek a merger/acquisition. The company has no product revenue and may never achieve profitability.
- Subsequent Events:
- On October 3, 2008, the company licensed exclusive worldwide rights to oral delivery of RNAi therapeutics from UMMS for a total fee of $2.5 million (payable in cash or equity).
- On October 17, 2008, the company granted options to purchase 201,000 shares to employees.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12.7 million in liquid assets to cover the projected burn rate through late 2009, given the increasing G&A and R&D expenses.
- Financing Needs: Confirm the status of any potential equity raises or partnership agreements required to fund the $2.5 million license fee and ongoing operations beyond 2009.
- Stock-Based Compensation: Review the impact of non-cash stock-based compensation ($3.2 million for the nine months) on the reported net loss and future dilution.
- License Obligations: Assess the terms of the new October 2008 license agreement with UMMS, specifically the cash vs. equity payment structure and milestone obligations.